about
Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk ReductionMechanistic systems modeling to guide drug discovery and developmentSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementJeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease.Atherosclerosis regression and high-density lipoproteins.An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.Ongoing challenges for pharmacotherapy for dyslipidemia.Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Newer antiatherosclerosis treatment strategies.The DEFINE study: a bright future for CETP inhibitors?The role of monocytosis and neutrophilia in atherosclerosis.
P2860
Q29999973-1C88BD5A-1EBE-4FCF-8B99-BE11936B3B59Q30414988-B4D1EBD6-7E43-4084-BE31-900BCF3CA58DQ34120778-7CD28240-6A29-4177-9C3F-921914F84D39Q34181381-9C93A916-0E8F-43DB-A7FF-DAC96D03B4D8Q35049058-89BB336D-65F2-4BE1-B7A2-EACEF5018AC4Q36030580-CA77FAB0-6AB8-4E38-A1CE-8F1A13074565Q37786650-CC05EB6E-F958-4EA9-88F6-71401B41B8CBQ38032616-BBA40460-A3FA-4F23-AB27-A6F0C8F03842Q38048831-AB5EEF65-A1E9-41C1-8CBE-87F3ED2F6B53Q38051303-6728348F-70A3-4F68-9F97-C0CCB876018BQ38283386-77F67CEC-12BB-4AAC-B807-E9C1ACBDEE87Q38418951-82B562B2-026E-462D-87E9-58231CE37065Q38832774-1CA244F7-37C5-4171-B94B-3CCB6F88C48DQ42737139-8BEE3ABA-984E-4647-8808-9E7B9BFA36E9Q43439911-21476A46-4F8B-4CA0-B1BC-74D4BBF5B8A6Q48175299-824AF71B-CE8C-4560-B35F-06F5E423C2F5
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Dalcetrapib: a review of Phase II data.
@ast
Dalcetrapib: a review of Phase II data.
@en
Dalcetrapib: a review of Phase II data.
@nl
type
label
Dalcetrapib: a review of Phase II data.
@ast
Dalcetrapib: a review of Phase II data.
@en
Dalcetrapib: a review of Phase II data.
@nl
prefLabel
Dalcetrapib: a review of Phase II data.
@ast
Dalcetrapib: a review of Phase II data.
@en
Dalcetrapib: a review of Phase II data.
@nl
P2860
P1476
Dalcetrapib: a review of Phase II data.
@en
P2093
Jennifer G Robinson
P2860
P304
P356
10.1517/13543784.2010.488219
P407
P577
2010-06-01T00:00:00Z